BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18727626)

  • 21. [Prenatal immunoglobulin prevention in Rh(D)-negative nonsensitized pregnant women].
    Katsulov A
    Akush Ginekol (Sofiia); 1997; 36(2):1-2. PubMed ID: 9471891
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of Rh immune globulin: a review.
    Sutton GP; Jay A; Lim YS; Noland JE; Boral LI
    Indiana Med; 1988 Apr; 81(4):321-2. PubMed ID: 2834434
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
    Okwundu CI; Afolabi BB
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical significance of anti-G in alloimmunized pregnant women.
    Hadley A; Poole J; Poole G
    Transfusion; 1997 Sep; 37(9):985. PubMed ID: 9308650
    [No Abstract]   [Full Text] [Related]  

  • 26. Efforts should be made to eradicate Rh hemolytic disease of the fetus and newborn.
    Caiola G
    Obstet Gynecol Surv; 1984 Jan; 39(1):55-7. PubMed ID: 6320075
    [No Abstract]   [Full Text] [Related]  

  • 27. Preventing RhD haemolytic disease of the newborn. Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis.
    Lee D
    BMJ; 1998 May; 316(7144):1611. PubMed ID: 9596614
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanism of anti-D-mediated immune suppression--a paradox awaiting resolution?
    Kumpel BM; Elson CJ
    Trends Immunol; 2001 Jan; 22(1):26-31. PubMed ID: 11286688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rhesus immunization in pregnancy: a review.
    Duerbeck NB; Seeds JW
    Obstet Gynecol Surv; 1993 Dec; 48(12):801-10. PubMed ID: 8309663
    [No Abstract]   [Full Text] [Related]  

  • 30. Decline in deaths from rhesus haemolytic disease of the newborn.
    Clarke C; Hussey RM
    J R Coll Physicians Lond; 1994; 28(4):310-1. PubMed ID: 7965968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidemiology of anti-D allo-immunization during pregnancy].
    Branger B; Winer N
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S87-1S92. PubMed ID: 16495833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Curr Opin Mol Ther; 2010 Dec; 12(6):734-40. PubMed ID: 21154165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The history of rhesus prophylaxis with anti-D.
    Wegmann A; Glück R
    Eur J Pediatr; 1996 Oct; 155(10):835-8. PubMed ID: 8891551
    [No Abstract]   [Full Text] [Related]  

  • 34. [The expediency of producing antirhesus-Rh0(D) immunoglobulin and its use for preventing hemolytic disease of the newborn (for discussion)].
    Mikhaĭlova AA; Klimova NIa
    Gematol Transfuziol; 1992; 37(7-8):39-40. PubMed ID: 1342987
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical significance of anti-G.
    Lenkiewicz B; Zupańska B
    Transfus Med; 2002 Jun; 12(3):221. PubMed ID: 12071879
    [No Abstract]   [Full Text] [Related]  

  • 36. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children.
    Pegoraro V; Urbinati D; Visser GHA; Di Renzo GC; Zipursky A; Stotler BA; Spitalnik SL
    PLoS One; 2020; 15(7):e0235807. PubMed ID: 32687543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A curious case of anti-D antibody titer.
    Hensley JG; Coughlin KP; Klein LL
    J Midwifery Womens Health; 2009; 54(6):497-502. PubMed ID: 19879523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing RhD haemolytic disease of the newborn. Services should be centralised for pregnancies affected by RhD haemolytic disease.
    Craig JS; McClure BG; Tubman TR
    BMJ; 1998 May; 316(7144):1611. PubMed ID: 9616034
    [No Abstract]   [Full Text] [Related]  

  • 40. The introduction of human monoclonal anti-D for therapeutic use.
    Fletcher A; Thomson A
    Transfus Med Rev; 1995 Oct; 9(4):314-26. PubMed ID: 8541714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.